Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. - Wikidata - awgldk - TriplyDB

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

http://www.wikidata.org/entity/Q35140097

about

Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Aberrant B-cell homeostasis in chronic GVHD Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice Syk and tired of current chronic GVHD therapies.Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Augmentation of Recipient Adaptive Alloimmunity by Donor Passenger Lymphocytes within the Transplant Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.State-of-the-art acute and chronic GVHD treatment.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.Emerging drugs for graft-versus-host disease.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.American Society of Hematology Annual Meeting and Exposition.Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia Ibrutinib treatment improves T cell number and function in CLL patients.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.New and emerging therapies for acute and chronic graft versus host disease.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.Role of Bruton's tyrosine kinase in B cells and malignancies.B-cell targeting in chronic Graft-versus-Host disease.Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

P2860

Q26851417-749079BD-FA30-4565-865A-B943DCAA48C4 Q28076264-AA2DC0EA-D9BA-47D1-B2A5-CA24221AD2CD Q33798102-4633C540-E5EA-4534-B8CA-5B2DA49147C8 Q35171251-32F21D21-7770-44E1-B8C9-60523ECB30FA Q35586614-8F99B110-0959-411D-8732-D62B506FF4F6 Q35766798-911D1330-A80F-4C53-B4B0-0B9F4827BC70 Q35784487-A27D3EC9-646E-4BAD-BBC5-2B3760BB568D Q35784522-7289EE2C-35C9-4389-8B2B-0039B2CE163C Q36220062-6A58A08E-B319-4CEE-BA55-9842B54CC943 Q36471247-2B34DB49-EA37-48C2-B953-E0CD9934FAEE Q36759124-EC6F140E-9396-45C4-BDB4-CDDE8B1A2BD5 Q36851405-6E4A3E33-AEA2-43B6-9680-FD518ECD9841 Q36876981-F73669FB-7434-4A41-828A-A51F0D0B5D3A Q36910447-45538A13-436B-48C3-BF78-9055261714CF Q37035815-AE6EB249-0391-4EC9-9EC5-B73B6E48527B Q37241480-D390E1BE-4548-40C4-88E5-022F0645CDBE Q37276584-57712735-5FCA-4C42-9558-42511426B516 Q37528067-CF15663B-CAC1-410B-A62E-8F602519ED96 Q38392246-1F7605B7-9ED4-405C-BDF3-52F9151159D9 Q38416376-C7574527-B547-4519-BBED-325153EC8F9E Q38765458-24507407-0C22-4BA6-A545-535D231C4986 Q38786084-66468046-2B71-400E-A99E-76629DD146A9 Q39002164-FA39B46C-BF20-4941-AAAA-8FCFA00DAF1B Q39002166-D999C38F-0AA8-48E7-BBD6-3C81E3A1A22A Q39023963-59E107B5-2AB4-4244-9FC3-8D1A18774411 Q39401817-4AD5ADBB-0368-41B4-8B97-C14A20EAC1DF Q40122845-26042B17-91A7-44BE-94B1-60B7D7F96D99 Q40291708-8A7FB161-ED0D-4CF6-972D-66AECE5E515F Q41996454-200F75B6-9FD4-462E-918A-28C5A857D3EB Q42379668-1A06835D-DB93-4099-9BEF-5D72E2E95A72 Q42406408-F3CCD0FC-61D6-48BA-8309-69762A95A258 Q42909982-29DB8A4A-A5BC-4416-B6A2-2DBC808A8B66 Q46428638-BF605D21-BA26-461C-B769-0602B04468CC Q47709978-AD4C61DF-ED02-4BF6-8F03-8E00F4B573F3 Q49238507-A368B7B3-BC7C-4F28-8EAA-51701706281A Q49384876-E38C9B02-4FF6-4A49-A3D2-BE1789596402 Q49546562-DB7A80D9-3801-4F6A-A1C5-7044499CB28C Q49888075-16E5C585-2219-40CD-A6B2-66C5BE7D25F5 Q50044417-CB51D2FE-69C2-4448-9F69-43A08D9F968D Q50065065-93AE3D39-F59E-472A-8B72-CC646DB2F9F0

P2860

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

http://www.wikidata.org/entity/Q35140097

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@ast

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@en

type

label

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@ast

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@en

prefLabel

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@ast

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@en

P1433

Q35140097-8CBDBF16-4DCC-410B-870F-B1F1B25989DA

P1476

Q35140097-82A38A5D-9F92-45F6-91C2-E372190C5C97

P2093

Q35140097-0023CD0F-3841-47B6-9BE1-DA54BB97A5C4

Q35140097-086FE921-0B93-404A-89EA-7AF3F82EC03D

Q35140097-0E495FFF-2B2F-4CD7-B267-A3714E37678D

Q35140097-15E20EBE-ECCF-4E01-8957-167D7FF6D7C2

Q35140097-2146AB12-7757-4642-8212-F27C91DBD95C

Q35140097-2156AB23-9C0F-4BDF-B7D9-1905AF5FE618

Q35140097-39C58AEA-01CD-41F6-8D1C-A7D361DD553F

Q35140097-5113B77C-EB51-4F1D-B615-43D4543D47D6

Q35140097-709CFCA4-9735-4D53-B9AF-CED052D93103

Q35140097-75B5EAE4-4B26-440C-8B91-7072EC97D4D2

P2860

Q35140097-0147026A-A059-435B-90CC-DD8C122C3A5E

Q35140097-049413A3-0CD8-4EA7-933A-C145884231FD

Q35140097-06CF1E65-2154-489A-B8F0-76829DC08B57

Q35140097-0B4C9BB1-15D4-476D-B38B-18E31CE6ADB9

Q35140097-0CF9BE5D-36B3-46B2-B634-991F93E2C677

Q35140097-1756A374-7512-4C76-A170-47509DFFA39C

Q35140097-18B8E707-6404-4DA8-9CFC-7C20580E0804

Q35140097-232E6F15-8BD6-4BB0-84D9-D307AB172CBD

Q35140097-23EEDAC9-CAC5-4175-9441-EE4428401A16

Q35140097-3023F594-39B9-4A4F-A63A-4D298653B079

P304

Q35140097-94D78A37-9A09-443D-8F5E-526199C7EFC4

P31

Q35140097-0B586AE1-30B2-4913-AD30-8359865544B9

P356

Q35140097-F83EC8D8-C1B1-416C-9207-4B53ABC7C387

P407

Q35140097-8CBFCFE0-9172-4A8E-9657-50D363D2B7B6

P433

Q35140097-74369C7F-22E3-47DE-99B5-F073BBBA86B7

P478

Q35140097-E1ECF37B-9AC6-4FF2-8B80-A395E1BE8D89

P50

Q35140097-0552EEC1-EC1E-4BF4-81AE-CE0710C51C12

Q35140097-65777A3B-B5E1-49F8-98B7-4C310B2965B7

Q35140097-6D1AA7E9-C818-4E79-AFDE-F852D2E5F220

Q35140097-6F501736-625F-424A-B23F-F9737A26DB6F

Q35140097-7BA66B7A-76CF-4A68-AC94-1107B32C5D60

Q35140097-900A9D8F-BEF0-4A7F-A097-26C32D9A5033

Q35140097-EDAC5924-6F83-442D-8E25-573FC8B7D90A

Q35140097-F68ADBF2-A20F-4023-9FD5-096BB7506AA7

P577

Q35140097-8C73B683-F46A-4A69-B2F1-D2F3CE1A3EFA

P5875

Q35140097-BFEA2A69-EE84-4DE8-9011-1B4970AA2AB1

P698

Q35140097-A02F8F55-52E1-4A55-8B1B-DE08201AEB76

P932

Q35140097-CF71BF89-D2FC-40A0-A344-3B8471E8AE4E

P356

P1433

Journal of Clinical Investigation

P1476

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Amy Lehman

http://www.w3.org/2001/XMLSchema#string

Carrie Yang

http://www.w3.org/2001/XMLSchema#string

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

David H Munn

http://www.w3.org/2001/XMLSchema#string

Henry K Wong

http://www.w3.org/2001/XMLSchema#string

Ivan Maillard

http://www.w3.org/2001/XMLSchema#string

Jason A Dubovsky

http://www.w3.org/2001/XMLSchema#string

Jing Du

http://www.w3.org/2001/XMLSchema#string

John Koreth

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Treatment of chronic graft-versus-host disease in 2011

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.

Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience.

P304

4867-4876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI75328

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan S. Serody

Geoffrey R Hill

Benjamin Kaffenberger

Bonnie K Harrington

Angela Panoskaltsis-Mortari

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266326030

http://www.w3.org/2001/XMLSchema#string

P698

25271622

http://www.w3.org/2001/XMLSchema#string

P932

4347242

http://www.w3.org/2001/XMLSchema#string